Company logo

SYK - Stryker Corporation

NYSE -> Healthcare -> Medical Devices
Kalamazoo, United States
Type: Equity

SYK price evolution
SYK
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $2971 $1860 $1401 $1671
Short term investments $82 $76 $77 $86
Net receivables $3765 $3276 $3261 $3215
Inventory $4843 $4883 $4593 $4333
Total current assets $12487 $11045 $10151 $10155
Long term investments
Property, plant & equipment $3215 $3106 $3082 $3037
Goodwill & intangible assets $19836 $19869 $20089 $19628
Total noncurrent assets $27394 $26997 $27258 $26675
Total investments $82 $76 $77 $86
Total assets $39881 $38042 $37409 $36830
Current liabilities
Accounts payable $1517 $1296 $1326 $1366
Deferred revenue
Short long term debt $2094 $2308 $1798 $1204
Total current liabilities $7890 $7458 $6584 $5866
Long term debt $10901 $10382 $11149 $11857
Total noncurrent liabilities $13398 $12679 $13464 $14069
Total debt $12995 $12690 $12947 $13061
Total liabilities $21288 $20137 $20048 $19935
Shareholders' equity
Retained earnings $16771 $15933 $15526 $15072
Other shareholder equity $18593 -$249 -$330 -$305
Total shareholder equity $18593 $17905 $17361 $16895
(in millions $) 31 Jan 2024 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $2971 $1844 $2944 $2943
Short term investments $82 $84 $75 $81
Net receivables $3765 $3565 $3022 $2701
Inventory $4843 $3995 $3314 $3494
Total current assets $12487 $10275 $10017 $9707
Long term investments
Property, plant & equipment $3215 $2970 $2833 $2752
Goodwill & intangible assets $19836 $19765 $17758 $18332
Total noncurrent assets $27394 $26609 $24614 $24623
Total investments $82 $84 $75 $81
Total assets $39881 $36884 $34631 $34330
Current liabilities
Accounts payable $1517 $1413 $1129 $810
Deferred revenue
Short long term debt $2094 $1191 $7 $761
Total current liabilities $7890 $6303 $4549 $5041
Long term debt $10901 $11857 $12472 $13230
Total noncurrent liabilities $13398 $13965 $15205 $16205
Total debt $12995 $13048 $12479 $13991
Total liabilities $21288 $20268 $19754 $21246
Shareholders' equity
Retained earnings $16771 $14765 $13480 $12462
Other shareholder equity $18593 $16616 -$531 -$1157
Total shareholder equity $18593 $16616 $14877 $13084
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $5815 $4909 $4996 $4778
Cost of revenue $1751 $1815 $1762
Gross Profit $3713 $3158 $3181 $3016
Operating activities
Research & development $353 $346 $339
Selling, general & administrative $1701 $1706 $1781
Total operating expenses $2278 $2227 $2216 $2281
Operating income $931 $965 $735
Income from continuing operations
EBIT $869 $899 $679
Income tax expense $83 $177 $161 $87
Interest expense
Net income
Net income $1143 $692 $738 $592
Income (for common shares) $692 $738 $592
(in millions $) 31 Jan 2024 31 Dec 2022 31 Jan 2022 31 Dec 2020
Revenue
Total revenue $20498 $18449 $14351
Cost of revenue $6871 $5294
Gross Profit $13099 $11578 $9057
Operating activities
Research & development $1454 $984
Selling, general & administrative $6455 $5361
Total operating expenses $8779 $8737 $6834
Operating income $2841 $2223
Income from continuing operations
EBIT $2683 $1954
Income tax expense $508 $325 $355
Interest expense
Net income
Net income $3165 $2358 $1599
Income (for common shares) $2358 $1599
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income $692 $738 $592
Operating activities
Depreciation $98 $98 $96
Business acquisitions & disposals -$390
Stock-based compensation $52 $39 $74
Total cash flows from operations $1050 $688 $445
Investing activities
Capital expenditures -$148 -$152 -$130
Investments $1 $10 -$3
Total cash flows from investing -$962 -$145 -$533 -$132
Financing activities
Dividends paid -$1139 -$285 -$285 -$284
Sale and purchase of stock
Net borrowings -$107 -$103 -$102
Total cash flows from financing -$1594 -$422 -$405 -$481
Effect of exchange rate -$28 -$24 -$20 -$5
Change in cash and equivalents $1096 $459 -$270 -$173
(in millions $) 31 Jan 2024 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $2358 $1994 $1599
Operating activities
Depreciation $371 $371 $340
Business acquisitions & disposals -$2563 -$339 -$4222
Stock-based compensation $168 $171 $142
Total cash flows from operations $2624 $3263 $3277
Investing activities
Capital expenditures -$588 -$525 -$487
Investments $188 $6 $7
Total cash flows from investing -$962 -$2924 -$859 -$4701
Financing activities
Dividends paid -$1139 -$1051 -$950 -$863
Sale and purchase of stock
Net borrowings $472 -$1153 $989
Total cash flows from financing -$1594 -$749 -$2365 -$11
Effect of exchange rate -$28 -$51 -$38 $41
Change in cash and equivalents $1096 -$1100 $1 -$1394
News
Here's Why Investors Should Retain STERIS (STE) Stock for Now
Zacks via Yahoo Finance 28 Mar 2024
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
Zacks via Yahoo Finance 27 Mar 2024
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
Zacks via Yahoo Finance 27 Mar 2024
Stryker's (NYSE:SYK) Dividend Will Be $0.80
Simply Wall St. via Yahoo Finance 26 Mar 2024
14 Best Medical Device Stocks To Buy Now
Insider Monkey via Yahoo Finance 24 Mar 2024
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
Zacks via Yahoo Finance 22 Mar 2024
Top Stock Reports for Disney, Morgan Stanley & Stryker
Zacks via Yahoo Finance 21 Mar 2024
Stryker Insiders Sell US$106m Of Stock, Possibly Signalling Caution
Simply Wall St. via Yahoo Finance 21 Mar 2024
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
Zacks 20 Mar 2024
Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA
Zacks via Yahoo Finance 20 Mar 2024
Fundamentals
Market cap $135.97B
Enterprise value $145.99B
Shares outstanding 379.94M
Revenue $20.50B
EBITDA N/A
EBIT N/A
Net Income $3.17B
Revenue Q/Q 11.78%
Revenue Y/Y 11.11%
P/E ratio 42.96
EV/Sales 7.12
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 6.63
P/B ratio InfinityT
Book/Share 0.00
Cash/Share 7.82
EPS $8.33
ROA 8.32%
ROE 17.89%
Debt/Equity 1.14
Net debt/EBITDA N/A
Current ratio 1.58
Quick ratio 0.97